Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Non-Current Assets (2022 - 2025)

Stoke Therapeutics (STOK) has 4 years of Non-Current Assets data on record, last reported at $87.8 million in Q3 2025.

  • For Q3 2025, Non-Current Assets rose 121.19% year-over-year to $87.8 million; the TTM value through Sep 2025 reached $272.3 million, up 261.26%, while the annual FY2024 figure was $38.8 million, 198.38% up from the prior year.
  • Non-Current Assets reached $87.8 million in Q3 2025 per STOK's latest filing, down from $114.5 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $114.5 million in Q2 2025 and bottomed at $9.9 million in Q3 2023.
  • Average Non-Current Assets over 4 years is $28.5 million, with a median of $12.3 million recorded in 2022.
  • Peak YoY movement for Non-Current Assets: fell 24.22% in 2023, then soared 964.18% in 2025.
  • A 4-year view of Non-Current Assets shows it stood at $12.0 million in 2022, then grew by 8.39% to $13.0 million in 2023, then surged by 198.38% to $38.8 million in 2024, then skyrocketed by 126.36% to $87.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Assets were $87.8 million in Q3 2025, $114.5 million in Q2 2025, and $31.2 million in Q1 2025.